In the news release, GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings, issued 17-Oct-2025 by GRAIL, Inc. over PR Newswire, we are advised by the company that updated media assets have been attached to the news release. The complete, updated release follows: GRAIL PATHFINDER 2 Results Show Galleri ® Multi-Cancer Early Detection Blood Test Increased Cancer Detection More Than Seven-Fold When Added to USPSTF A and B Recommended Screenings More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do N

More Than Half of Cancers Detected by Galleri Were Early Stage Approximately Three-Quarters of Galleri-Detected Cancers Do Not Have Recommended Screenings PATHFINDER 2 is the Largest U.S. Multi-Cancer Early Detection (MCED) Interventional Study in the Cancer Screening Population  MENLO PARK, Calif., Oct. 17, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from its registrational PATHFINDER 2 study are being presented at the European Society for Medical Oncology (ESMO) Congress 20251. 

Samsung C&T and Samsung Electronics Will Make an Equity Investment of $110 Million Into GRAIL, Subject to Closing Conditions Samsung C&T Will Drive Commercialization of Galleri in South Korea With Possible Expansion to Japan and Singapore Samsung Electronics and GRAIL Will Also Explore Potential Strategic and Operational Collaborations SEOUL, Korea and MENLO PARK, Calif., Oct. 16, 2025 /PRNewswire/ -- Samsung C&T (SCT), Samsung Electronics (SEC), and GRAIL, Inc. (NASDAQ:GRAL), today announced they have signed a binding Letter of Intent for a strategic collaboration to bring GRAIL's GalleriⓇ multi-cancer early detection (MCED) test to key Asian markets. SCT and SEC have also agreed to invest

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket Approval Application (PMA) Updated SYMPLIFY and REFLECTION Study Results to be Presented at the Early Detection of Cancer Conference (EDCC) Highlight Galleri Performance in Symptomatic and Veteran Populations, Respectively MENLO PARK, Calif., Sept. 23, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present new data highlighting the Galleri® multi-cancer early detection (MCED) test performance and safety from

MENLO PARK, Calif., Sept. 10, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at Bernstein Insights: Healthcare Leaders and Disruptors – 2nd Annual Healthcare Forum on Wednesday, Sep. 24 at 8:00 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare

MENLO PARK, Calif., Aug. 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 47,150 shares of GRAIL's common stock to 27 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

MENLO PARK, Calif., Aug. 26, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, Sep. 9 at 1:50 p.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission is to

Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be Submitted for Presentation at ESMO 2025 in October MENLO PARK, Calif., Aug. 12, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2025. Total revenue in the second quarter grew 11% year-over-year to $35.5 million, and Galleri revenue gr

MENLO PARK, Calif., July 30, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on Wednesday, Aug. 13 at 8:30 a.m. ET.  Live and replay webcasts may be accessed in the investor relations section of GRAIL's website at investors.grail.com. The webcast will be archived and available for reply for at least 30 days after the event. About GRAILGRAIL is a healthcare company whose mission i

MENLO PARK, Calif., July 29, 2025 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2025 following the close of market on Tuesday, Aug. 12, 2025. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. Second Quarter 2025 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the inv

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

4 - GRAIL, Inc. (0001699031) (Issuer)

8-K - GRAIL, Inc. (0001699031) (Filer)

144 - GRAIL, Inc. (0001699031) (Subject)

SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)

SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)

8-K - GRAIL, Inc. (0001699031) (Filer)

144 - GRAIL, Inc. (0001699031) (Subject)

SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)

10-Q - GRAIL, Inc. (0001699031) (Filer)

8-K - GRAIL, Inc. (0001699031) (Filer)

SCHEDULE 13G - GRAIL, Inc. (0001699031) (Subject)

MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees